ArticleIranian journal of pharmaceutical research : IJPR
Baicalein Protects H9c2 Cardiomyoblasts Against LPS-Induced Inflammatory Injury by Modulating the NF-κB/NLRP3 Inflammasome Pathway and Mitochondrial ROS.
Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis-related cardiomyopathy is mainly induced by uncontrolled inflammation and mitochondrial oxidative damage triggered by endotoxins, especially those of Gram-negative bacteria. Lipopolysaccharide (LPS), an endotoxin, activates the Toll-like receptor 4/nuclear factor kappa B (TLR4/NF-κB) signaling pathway and the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome, which further activates caspase-1 to process the pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18). Chronic activation of this signaling pathway is responsible for mitochondrial damage and loss of membrane potential. Baicalein, a flavonoid derived from the herbal plant Objectives: In this study, we assessed whether baicalein has a protective effect on H9c2 cardiomyoblasts against inflammatory and mitochondrial injury induced by LPS through regulation of inflammatory pathways involving NF-κB, the inflammasome, caspase-1 activity, cytokine expression, and oxidation. Methods: H9c2 cells were pre-exposed to different baicalein concentrations (5 - 20 µM) and, after 1 hour, exposed to 1 µg/mL of LPS. Analysis included cell viability measurements by MTT assay, lactate dehydrogenase (LDH) release, and microscopic evaluation by phase-contrast microscopy. Expression levels of premature Nlrp3, Il1B, Il18, and Casp1 (0 - 4 h) were analyzed by real-time polymerase chain reaction (PCR). Protein levels of inflammasome and NF-κB pathway proteins were evaluated by immunoblot analysis. Activity of caspase-1 and cytokine secretion of IL-1β and IL-18 were evaluated by colorimetry and enzyme-linked immunosorbent assay (ELISA), respectively. Mitochondrial membrane potential (ΔΨm) was evaluated by staining with JC1 dye, and reactive oxygen species (ROS) levels were evaluated by fluorescence with DCFH2DA; N-acetylcysteine (NAC) was used as an antioxidant positive control. Results: LPS strongly elevated the transcription of Nlrp3 and Il1b at 2 hours, in addition to enhancing protein expression of NLRP3, activity of caspase-1, and secretion of IL-1β and IL-18. Underlying these pro-inflammatory responses were mitochondrial depolarization, augmented ROS production, diminished cell survival, and cytotoxicity. Prior administration of baicalein mitigated NF-κB activation, diminished priming of the inflammasome response at both transcriptional and protein levels, and decreased caspase-1 activity and secretion of the cytokines. Moreover, baicalein maintained mitochondrial membrane potential and diminished ROS within the cells, comparable to NAC, and improved cellular viability and morphology. Conclusions: Baicalein confers substantial protection against LPS-induced inflammatory and oxidative damage in H9c2 cardiomyoblasts by concurrently suppressing NF-κB activation, mitigating NLRP3 inflammasome signaling, curbing caspase-1-driven cytokine maturation, and stabilizing mitochondrial function through reduction of ROS. These findings identify baicalein as a promising candidate for targeting the ROS-inflammasome axis in sepsis-associated cardiac dysfunction and related inflammatory cardiac disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.